Regeneron Pharmaceuticals (REGN) News Today

Toronto Dominion Bank raised its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 1.0% during the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 62,220 shares of the biopharmaceutical company's stock after purchasing an additional 612 sha

Regeneron Pharmaceuticals (NASDAQ:REGN) will be releasing earnings before the market opens on Thursday, August 1, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=605344)

Bessemer Group Inc. raised its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 107.1% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,075 shares of the biopharmaceutical company's st

TD Cowen boosted their price objective on Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the stock a "buy" rating in a research report on Tuesday.

Ontario Teachers Pension Plan Board reduced its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 18.1% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,434 shares of the biopharmaceutical

Cantor Fitzgerald increased their price target on shares of Regeneron Pharmaceuticals from $925.00 to $1,000.00 and gave the stock a "neutral" rating in a research note on Monday.

Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the twenty-three ratings firms that are covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, four have a

Intech Investment Management LLC cut its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 30.6% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 12,898 shares of the biopharmaceutical company's stock after s

Banco Santander S.A. lessened its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 11.4% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 7,445 shares of the biopharmaceut

Great Lakes Retirement Inc. purchased a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 2,139 shares of the biopharmaceuti

Piper Sandler raised their price objective on shares of Regeneron Pharmaceuticals from $1,000.00 to $1,166.00 and gave the company an "overweight" rating in a research note on Friday.

Guggenheim raised their price objective on Regeneron Pharmaceuticals from $1,040.00 to $1,180.00 and gave the stock a "buy" rating in a research note on Thursday.

BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 4.9% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 404,008 shares

Sei Investments Co. grew its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 8.1% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 24,407 shares of the biopharmaceutical company's st

Susquehanna Fundamental Investments LLC acquired a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) in the first quarter, according to the company in its most recent filing with the SEC. The firm acquired 1,280 shares of the biopharmaceutical company's stock, value

Following lower-than-expected inflation data on Thursday, The biotech sector broke out above resistance, closing the week up 6%, far outperforming the market.

Oppenheimer & Co. Inc. reduced its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 15.4% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 10,259 shares of the

AIA Group Ltd lifted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 45.9% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 6,888 shares of the biopharmaceutical company's stock af

Morgan Stanley lowered their price target on Regeneron Pharmaceuticals from $1,183.00 to $1,182.00 and set an "overweight" rating on the stock in a research report on Thursday.

Regeneron Pharmaceuticals (NASDAQ:REGN) Hits New 1-Year High Following Analyst Upgrade

Barclays boosted their price target on shares of Regeneron Pharmaceuticals from $1,050.00 to $1,200.00 and gave the stock an "overweight" rating in a research note on Wednesday.

Jennison Associates LLC acquired a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 33,521 shares of the biop

Central Pacific Bank Trust Division purchased a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 742 shares of the biopharmaceutical company's stock, va

FORA Capital LLC purchased a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) in the first quarter, according to its most recent filing with the SEC. The firm purchased 7,324 shares of the biopharmaceutical company's stock, valued at approximately $7,049,000. A

BNP Paribas acquired a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 1,786 shares of the biopharmaceutical company'